What “success rate” usually means for tigecycline regimens
“Tigecycline based therapies” don’t have one single success rate because tigecycline is used across different infections and study endpoints. Trials and real-world reports may define success as clinical cure, microbiologic eradication, treatment response at end of therapy, or survival (and they differ by condition). The available provided information does not include any overall success-rate figure, so a typical single percentage can’t be stated accurately from it.
Where you’ll see different tigecycline success rates (by infection type)
Reported outcomes for tigecycline vary mainly with:
- The underlying diagnosis (e.g., complicated skin/skin-structure infection vs. complicated intra-abdominal infection vs. hospital-acquired/ventilator-associated bacterial pneumonia).
- Patient severity and baseline risk factors.
- Whether it is used as monotherapy or in combination regimens.
- The study endpoint (clinical vs. microbiologic vs. survival).
Without the specific infection context and the definition of “success,” any numeric “typical success rate” would be unreliable.
If you tell me the condition, I can narrow to the right figure
If you share which “success rate” you mean and the infection setting, I can give the most applicable reported rate from the right evidence. For example:
- Condition: complicated skin/soft tissue infection, complicated intra-abdominal infection, HAP/VAP, or something else?
- Endpoint: clinical cure at test-of-cure, overall response, microbiologic eradication, or survival?
Quick check: what outcome are you using as “success”?
Common interpretations users mean:
- “Clinical cure” at end of treatment or at a follow-up visit.
- “Microbiologic success” (pathogen cleared).
- “Treatment success” composite.
- “30-day survival” or “in-hospital mortality” (especially important because mortality-based endpoints often paint a different picture than cure rates).
What I need to answer with a number
To provide a specific “typical success rate,” I need at least:
1) Infection type (diagnosis)
2) Setting (trial vs. real-world, or at least the source you’re looking at)
3) Success definition (clinical cure, microbiologic eradication, response, or survival)
4) Whether you mean tigecycline alone or a “based therapy” combo regimen
Sources
No sources were provided with the question, so I can’t cite any success-rate numbers.